Abstract: Previous studies have indicated that cytotoxic treatments may induce or not activate viral lytic cycle activation in cancer cells latently infected by Kaposi's sarcoma-associated herpesvirus (KSHV). To investigate the molecular mechanisms responsible for such an effect, we compared two cytotoxic treatments able to induce the viral lytic cycle, named 12-O-tetradecanoylphorbol 13-acetate (TPA) (T) in combination with sodium butyrate (B) and bortezomib (BZ), with two cytotoxic treatments that did not activate this process, named metformin (MET) and quercetin (Q). Our results indicated that TB and bortezomib increased levels of oxygen reactive species (ROS) while metformin and quercetin reduced them. The finding that N-acetylcysteine (NAC), a reactive oxigen species (ROS) scavenger, counteracted K-bZIP expression induced by TB or bortezomib, confirmed that an ROS increase played a role in KSHV lytic cycle activation. Moreover, we found that TB and bortezomib up-regulated p62/Sequestosome1(p62/SQSTM1) protein, while metformin and quercetin down-regulated it. p62/SQSTM1 silencing or the inhibition of NF-E2-related factor 2 (NRF2) or Heat Shock Factor 1 (HSF1), that mediate p62/SQSTM1 transcription, also reduced KSHV lytic antigen expression induced by TB or bortezomib. Interestingly, such combination treatments further increased intracellular ROS and cytotoxicity induced by the single TB or bortezomib treatment, suggesting that NRF2, HSF1 and p62/SQSTM1 keep the ROS level under control, allowing primary effusion lymphoma (PEL) cells to continue to survive and KSHV to replicate.
Introduction
It has not been clarified why some cytotoxic treatments induce gammaherpesvirus replication in lymphoma cells harboring latent Epstein-Barr virus (EBV) or Kaposi sarcoma-associated herpesvirus (KSHV) infection. Lytic cycle activation may be considered a side effect of chemotherapies, since it leads to the expression of viral lytic antigens that may promote tumorigenesis. Particularly in the case of KSHV, viral replication and viral spread contribute to the maintenance of viral-associated
Materials and Methods

Cell Culture
BC3 (American Type Culture Collection, Manassas, VA, USA; ATCC) and BCBL1 (kindly provided by Prof. P. Monini, National AIDS Center, Istituto Superiore di Sanità, Rome, Italy) are human B-cell lines KSHV-infected, established from patients affected by primary effusion lymphoma (PEL). Cells were cultured in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA; 21870) supplemented with 10% fetal bovine serum (FBS) (Corning, NY, USA; 35-079), with L-glutamine and with streptomycin (100 µg/mL) (Corning, NY, USA; 30-002) and with penicillin (100 U/mL) (Corning, NY, USA; 25-005) in 5% CO 2 at 37 • C.
Cell Treatments
To induce viral replication, PEL cell lines were treated with either 12-O-tetradecanoylphorbol 13-acetate (TPA) (20 ng/mL) (Sigma Aldrich, St Louis, MO, USA; 185361) and sodium butyrate (B)
(0.3 mM) (Sigma Aldrich, St Louis, MO, USA; B5887) (TB), or with bortezomib (BZ) (20 nM) (Santa Cruz Biotechnology, Dallas, TX, USA; sc-217785) at the indicated times. BC3 and BCBL1 cell lines were treated with metformin (MET) (20 mM) (Sigma Aldrich, St Louis, MO, USA; D150659) or quercetin (Q) (50 µM) (Sigma Aldrich, St Louis, MO, USA; Q4951) at the indicated times [5, 16] . To evaluate the role of HSF1 and NRF2 during KSHV replication induced by TB or BZ, a time-course assay (from 5 to 10 µM) was performed with HSF1 inhibitor, KRIBB11 (HSF1 Inhibitor, I-HSF1), (Merck, Milano, Italy. 385570) or with NRF2 inhibitor, Brusatol (HSF1 Inhibitor, I-NRF2) (from 5 to 10 nM) (Sigma Aldrich, St Louis, MO, USA; 1868) for the indicated time. In some experiments, BC3 and BCBL1 were pre-treated with I-HSF1 (5 µM), I-NRF2 (5 nM) and/or with N-acetylcysteine (NAC) (5 mM) (Sigma Aldrich, St Louis, MO, USA; A7250), for 20 min and then cultured with TPA (20 ng/mL)/sodium butyrate (0.3 mM) for the indicated time. In some experiments, BC3 cells were treated with TB in the presence of H 2 O 2 (100 µM) for the indicated time.
In order to investigate autophagy, cells were treated with TPA (20 ng/mL)/sodium butyrate (0.3 mM) in the presence or absence of Bafilomycin A1 (BAF) (20 nM) (Santa Cruz Biotechnology Inc., Dallas, TX, USA; sc-201550), an inhibitor of vacuolar-H + -ATPase, for the final 4 h.
Cell Assay Viability
BC3 and BCBL1 cell lines were plated in 12-well plates at a density of 8 × 10 5 cells/well. Cells were pre-treated with I-HSF1 (5 µM), I-NRF2 (5 nM) or I-HSP70 (10 µM) and then cultured with either TPA (20 ng/mL) and sodium butyrate (0.3 mM) (TB) or bortezomib (BZ) (20 nM) for 24 h in the presence or absence of NAC or H 2 O 2 .
The BC3 cell line was transiently transfected with a specific RNA duplex to knock-down NRF2 for 48 h and then treated with TPA (20 ng/mL) and sodium butyrate (0.2 mM) (TB) or bortezomib (BZ) (20 nM) for the last 24 h.
A trypan blue (Sigma Aldrich, St Louis, MO, USA; 72571) exclusion assay was performed to test cell viability. Live cells were counted by light microscopy using a Neubauer hemocytometer.
Antibodies
In western blotting, we used the following primary antibodies: mouse monoclonal anti-K-bZIP (1:300) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-69797), mouse monoclonal anti-gp64 (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-65444), mouse monoclonal anti-SQSTM1 (1:500) (BD Transduction Laboratories, San Jose, CA, USA; cat. no. 610833), rabbit polyclonal anti-Microtubule-Associated protein 1 light chain 3 (LC3) (1:1000) (Novus Biologicals, Cambridge, UK; NB100-2220SS), mouse monoclonal anti-HSP70 (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-66049), mouse monoclonal anti-NRF2 (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-365949), rabbit polyclonal anti-p21 (1:500) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-397). Mouse monoclonal anti-β-actin (1:10000) (Sigma Aldrich, St Louis, MO, USA; A5441) (1:10000) was used as the loading control. The goat polyclonal anti-mouse IgG-horseradish peroxidase (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-2005) and anti-rabbit IgG-HRP (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-2004) were used as secondary antibodies. All the primary and secondary antibodies were diluted in PBS-0.1% Tween20 solution containing 3% of BSA (SERVA, Reno, NV, USA; 11943.03).
In the immunofluorescence assay, mouse monoclonal anti-K-bZIP (1:300) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-69797) or mouse monoclonal anti-gp64 (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-65444) was diluted in 1XPBS and used to evaluate the KSHV lytic cycle.
Western Blot Analysis
1 × 10 6 PEL cells were washed twice with 1X PBS and centrifuged at 1500 rpm for 5 min. Cells were lysed in a 1X RIPA buffer containing 150 mM Nacl, 1% NP-40 (Sigma Aldrich, NP40S), 50 mM Tris-HCl, pH 8, 0.5% deoxycholic acid (Sigma Aldrich, D6750), 0.1% SDS (Sigma Aldrich, . Following this, 10 µg of protein lysates were subjected to electrophoresis on 10% or 15% acrylamide gels. Gels were transferred to nitrocellulose membranes (Bio-Rad, 162-0115) for 2 h in Tris-glycine buffer. Membranes were blocked in PBS-0.1% Tween 20 solution containing 3% BSA, probed with specific antibodies and developed using ECL Blotting Substrate (Advansta, K-12045-D20).
Indirect Immunofluorescence Assay (IFA)
For immunofluorescence, BC3 and BCBL1 cell lines were treated either with TPA (20 ng/mL) and sodium butyrate (0.3 mM) or with bortezomib (20 nM) for 24 h with and without previous RNA interference to knock-down HSF1, NRF2 and SQSTM1 for 48 h. A total of 1 × 10 6 cells were centrifuged, washed in cold 1X PBS, seeded on glass slides and air dried. Cells were fixed in 2% paraformaldehyde for 30 min and then made permeable with 0.2% Trinton X-100 (Sigma Aldrich, St Louis, MO, USA; T-8787) for 5 min at room temperature. Slides were incubated with mouse monoclonal anti-K-bZIP (1:300 in 1X PBS) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-69797), mouse monoclonal anti-gp64 (1:100) (Santa Cruz Biotechnology Inc., Heidelberg, Germany; sc-65444) or mouse monoclonal anti-p62/SQSTM1 (1:500 in 1X PBS) (BD Transduction Laboratories, San Jose, CA, USA; cat. no. 610833) antibody and washed three times in 1X PBS after 1 h. They were then incubated with polyclonal conjugated-Cy3 sheep anti-mouse antibody (Jackson ImmunoResearch, Cambridgeshire, UK; 515-165-062) (1:1000 in 1X PBS) for 30 min at room temperature and washed twice with 1X PBS. Cells were then incubated with 1 µg/mL of 4 ,6 -diamidino-2-phenylindole (DAPI) to stain nuclei and coverslips were mounted face down using a PBS-glycerol (1:1) solution. The immunofluorescence was analyzed using a Fluorescence microscope (Zeiss) equipped with an AxioCam MRM Rev.3 at ×40 magnification.
Endogenous Reactive Oxygen Species (ROS) Detection
To detect reactive oxygen species, BC3 and BCBL1 cells were treated with TPA (20 ng/mL) and sodium butyrate (0.3 mM) (TB), or with bortezomib (BZ) (20 nM) for 24 h. In some experiments, PEL cell lines were pre-treated with I-HSF1 (5 µM) and I-NRF2 (5 mM) and then cultured with TPA (T) (20 ng/mL)/ sodium butyrate (B) (0.3 mM) or bortezomib (BZ) (20 nM), as described above.
Cells were stained with 2 ,7 -dichlorofluorescein diacetate (DCFDA) (Thermo Fisher Scientific, Waltham, MA, USA; D399), a fluorogenic dye which diffuses into the cell. DCFDA is oxidized by ROS into 2 ,7 -dichlorofluorescein, a fluorescent compound which can be detected by fluorescence spectroscopy. Cells were twice washed 1X PBS and then incubated at 37 • C with 10 µM DCFDA for 15 min. PEL cells were analyzed in FL-1 by a FACScalibur flow cytometer (BD, USA). For each analysis 10,000 events were recorded [17] [18] [19] .
Transfection and Plasmids
The BC3 cell line was transiently transfected with empty vector (EV) or pDest-mCherry-EGFP-SQSTM1 (pSQSTM1) (kindly provided by Terje Johansen) [20] plasmid, using Lipofectamine 2000 as indicated by manufacture's instructions. Briefly, 5 × 10 5 cell were seeded into 12-wells plate in RPMI supplemented with 10% FBS and L-glutamine without antibiotics for 24 h. Then, 1 µg plasmid DNA and 3 µL Lipofectamine 2000/well were diluted in Opti-MEM medium. The mixture was added to cells for 48 h. Cells were treated with TPA (20 ng/mL) (T) and sodium butyrate (B) (0.3 mM) for the last 24 h. To evaluate the KSHV lytic activation, K-bZIP expression was assessed by western blotting assay. 
RNA Extraction
BCBL1 cell line was treated either with TPA (20 ng/mL) and sodium butyrate (0.3 mM), or with bortezomib (20 nM) for 6 h and RNA was extracted [22] . Briefly, cells were centrifuged and washed twice in cold 1X PBS. Then, cells were lysed using 1 mL TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA; 15596026) for 5 min at room temperature. Following this, 0.2 mL chloroform was added to the solution. To isolate total RNA, the mixture was centrifuged and 0.5mL isopropanol was added to the colorless upper aqueous phase. Extracted RNA was washed twice in 75% ethanol and then re-suspended in warmed RNAase-and DNAse-free water. To remove contaminating genomic DNA, 5 µg RNA was incubated with DNase I, according to the manufacturer's instructions (Sigma Aldrich, St Louis, MO, USA; 11284932001). RNA samples were collected and stored at −80 • C.
Reverse-Transcription Quantitative PCR (qRT-PCR) and Quantitative PCR (qPCR)
1 µg total RNA was used to synthesize single-stranded cDNA, using SuperScript III Reverse Transcriptase Kit (Thermo Fisher Scientific, Waltham, MA, USA; 18064014). A total of 2 µL/well (10 ng/sample) of template was mixed to SYBR Master (Applied Biosystems, Foster City, CA, USA; 4472908), RNAase-/DNAse-free water and primers in 20 µL volume.
To perform qRT-PCR, the following conditions were used: 50 • C for 2 min, 95 • C for 2 min, 95 • C for 15 s and 60 • C for 1 min (40 cycles). The following primers were used: SQSTM1 (FW GGAGCCAGAGAACAAGTACC; RW CTCGCTCTTTCAGTTTCATGTTC) ACTA(FWTCACCCACACTGTGCCATCCTACGA;RWCAGCGGAACCGCTCATTGCCAAT GG) [23, 24] .
Target mRNA level was normalized to housekeeping mRNA actin and analyzed, comparing treated (TB or BZ) to untreated samples.
To evaluate KSHV viral production, the BC3 cell line was pre-treated with I-HSF1 (5 µM) for 1 h and then with NAC (5 mM) for the last 30 min. Cells were treated with TPA (20 ng/mL) (T)/Butyrate (B) (0.3 mM) for 24 h. Supernatants were collected and qRT-PCR was performed to assess KSHV DNA using the HHV-8 Elite MGB kit (ELITechGroup, Puteaux, France; RTS038PLD).
Densitometric Analysis
The quantification of proteins bands was performed by densitometric analysis using the Image J software, which was downloaded from the NIH web site (available online: http://imagej.nih.gov).
Statistical Analysis
Results are represented by the mean ± standard deviation (SD) of at least three independent experiments. Differences were considered statistically significant for p-value <0.05. 
Results
TPA/Butyrate (TB) and Bortezomib (BZ) Increase Intracellular ROS and Promote KSHV Lytic Antigen Expression, while Quercetin (Q) and Metformin (MET) Reduce ROS and Do Not Induce This Effect in PEL Cells
We investigated the impact of four different cytotoxic treatments, namely TPA in combination with sodium butyrate (TB), bortezomib (BZ), quercetin (Q) and metformin (MET), on the activation of the KSHV lytic cycle in PEL cells. These drugs, able to induce apoptosis in these cells [3] [4] [5] 25] with similar kinetics ( Figure 1A) , were used at concentrations that inhibit 50% of cell survival. As shown in Figure 1B ,C, both TB and BZ induced the expression of early and late viral lytic antigens K-bZIP and gp64, respectively, as indicated by western blot or by IFA, while Q and MET failed do so. Searching for the mechanisms that could underlie these differing impacts on the lytic cycle activation, we found that TB and BZ increased ROS while MET and Q reduced them, as evaluated by FACS analysis using DCFDA staining (Figure 2A ). Similarly, TB and BZ increased ROS while MET and Q decreased them in BJAB, a B lymphoma cell line that does not harbor the viral genome (Figure 2A 
We investigated the impact of four different cytotoxic treatments, namely TPA in combination with sodium butyrate (TB), bortezomib (BZ), quercetin (Q) and metformin (MET), on the activation of the KSHV lytic cycle in PEL cells. These drugs, able to induce apoptosis in these cells [3] [4] [5] 25] with similar kinetics ( Figure 1A) , were used at concentrations that inhibit 50% of cell survival. As shown in Figure 1B ,C, both TB and BZ induced the expression of early and late viral lytic antigens K-bZIP and gp64, respectively, as indicated by western blot or by IFA, while Q and MET failed do so. Searching for the mechanisms that could underlie these differing impacts on the lytic cycle activation, we found that TB and BZ increased ROS while MET and Q reduced them, as evaluated by FACS analysis using DCFDA staining ( Figure 2A ). Similarly, TB and BZ increased ROS while MET and Q decreased them in BJAB, a B lymphoma cell line that does not harbor the viral genome (Figure 2A It has been reported that oxidative stress may lead to the up-regulation of p62/SQSTM1 expression [26] . Thus, we investigated if its expression could be up-regulated by TB or BZ treatment, to help cells cope with oxidative stress. As shown in Figure 3A , we found that p62/SQSTM1 accumulated after 6, 12 and 24 h of TB or BZ treatments, the same time points in which these drugs increased ROS and activated KSHV lytic antigen expression. Conversely, Q and MET, which reduced ROS and down-regulated p62/SQSTM1 expression, did not induce viral replication. The accumulation of p62/SQSTM1 in TB-and BZ-treated PEL cells was then demonstrated by IFA experiments that also evidenced its different intracellular localization in cells following TB or BZ treatment ( Figure 3B ). This could be due to the BZ-mediated activation of kinases phosphorylating p62/SQSTM1 and leading to the formation of larger aggresomes. Subsequently, we correlated p62/SQSTM1 up-regulation with ROS increase. The finding that p62/SQSTM1 expression decreased in the presence of the ROS scavenger NAC in TB-and BZ-treated cells indicated that oxidative stress played a role in increasing its expression ( Figure 3C 
p62/SQSTM1 is Up-Regulated by TB and BZ and Down-Regulated By MET And Q
It has been reported that oxidative stress may lead to the up-regulation of p62/SQSTM1 expression [26] . Thus, we investigated if its expression could be up-regulated by TB or BZ treatment, to help cells cope with oxidative stress. As shown in Figure 3A , we found that p62/SQSTM1 accumulated after 6, 12 and 24h of TB or BZ treatments, the same time points in which these drugs increased ROS and activated KSHV lytic antigen expression. Conversely, Q and MET, which reduced ROS and down-regulated p62/SQSTM1 expression, did not induce viral replication. The accumulation of p62/SQSTM1 in TB-and BZ-treated PEL cells was then demonstrated by IFA experiments that also evidenced its different intracellular localization in cells following TB or BZ treatment ( Figure 3B ). This could be due to the BZ-mediated activation of kinases phosphorylating p62/SQSTM1 and leading to the formation of larger aggresomes. Subsequently, we correlated p62/SQSTM1 up-regulation with ROS increase. The finding that p62/SQSTM1 expression decreased in the presence of the ROS scavenger NAC in TB-and BZ-treated cells indicated that oxidative stress played a role in increasing its expression ( Figure 3C ). The dashed rectangular box displays a zoomed-view of SQSTM1-positive cells. (C) p62/SQTM1 expression was evaluated in TB-and BZ-treated cells in the presence or absence of NAC. Densitometric analysis was performed using Image J software and the ratio of K-bZIP or SQSTM1 versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of at least three independent experiments. * p-value < 0.05.
p62/SQSTM1 Up-Regulation is not Dependent on Autophagy Reduction at 6 and 12 h, while Autophagy Inhibition Contributes to Its Accumulation at 24 h after TB or BZ Treatments
As p62/SQSTM1 is a protein mainly degraded through autophagy [11] , we evaluated whether p62/SQSTM1 accumulation in TB-and BZ-treated PEL cells could be due to the inhibition of autophagic flux. For this aim, we evaluated LC3-I/II expression in PEL cells treated with TB or BZ after 6-12 or 24 h of treatment, in the presence or absence of bafilomycin (BAF). Bafilomycin is an inhibitor of vacuolar H + ATPase (V-ATPase) that inhibits the last autophagic steps and thus LC3-II degradation, allowing us to better evaluate its formation. As shown in Figure 4A , after 6 and 12 h, LC3-II expression increased in cells treated with TB or BZ in the presence of BAF, indicating that the autophagic flux was complete and that p62 accumulation did not depend on the reduction of autophagy at these time points. Similar to our previous findings [27] , after 24 h of TB or BZ treatment LC3-II did not further accumulate in the presence of BAF in comparison to control cells (see Figure 4A ), indicating that autophagy was blocked in the final stages and contributed to p62/SQSTM1 accumulation. We then investigated whether the p62/SQSTM1 up-regulation observed after 6 h of TB or BZ treatment was dependent on mRNA increase. Towards this aim, we performed qRT-PCR analysis and, as shown in in Figure 4B , we found that SQSTM1 mRNA increased in cells undergoing TB or BZ treatment. These results suggest that an increase of transcription and/or changes in mRNA stability and degradation could be leading to the up-regulation of p62/SQSTM1 observed at the time in which the autophagic flux was complete. 
p62/SQSTM1 Plays a Role in KSHV Lytic Antigen Expression Induced by TB or BZ
As p62/SQSTM1 expression increased in PEL cells undergoing TB or BZ, the same treatments that induced KSHV lytic cycle, the role of p62/SQSTM1 in this process was evaluated. We performed SQSTM1 knocking-down by using specific siRNA and found that it led to a reduction of K-bZIP expression in PEL cells treated with TB or BZ ( Figure 5A ). These results were confirmed by immunofluorescence experiments that showed a reduction of K-bZIP-positive cells after SQSTM1 silencing ( Figure 5B ), further indicating that p62/SQSTM1 plays a role in KSHV lytic antigen expression induced by TB or BZ in PEL cells. To confirm the importance of p62/SQSTM1 in supporting the KSHV lytic cycle, we also overexpressed this molecule by using a plasmid expression vector and, as shown in Figure 5C , p62/SQSTM1 overexpression caused increased K-bZIP expression in TB-treated cells. TB or BZ. Both p62/SQSTM1 and K-bZIP expression were evaluated by western blotting, and siRNASC was used as a control. Densitometric analysis was performed using Image J software and the ratio of p62/SQSTM1 and K-bZIP versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of three independent experiments. p* < 0.05 (siRNA SQSTM1 vs siRNA SC), p** < 0.05 (siRNA SQSTM1 vs siRNA SC; TB-treated) and p*** < 0.05 (siRNA SQSTM1 vs siRNA SC; BZ-treated) (B). K-bZIP expression (red staining) was evaluated by immunofluorescence assay in SQSTM1 knocked-down BCBL1 cells. The percentage of K-bZIP-positive cells is indicated. DAPI was used to stain nuclei (blue). Images are 40× magnification. All results are representative of three independent experiments. (C) K-bZIP expression in TB-treated BC3 cells overexpressing SQSTM1, as evaluated by western blot analysis. Densitometric analysis was performed using Image J software and the ratio of p62/SQSTM1 and K-bZIP versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of three independent experiments. p* < 0.05 (TB vs CT; EV-transfection)and p** < 0.05 (TB vs CT; pSQSTM1-transfection).
The Main Mediators of Cell Stress
Responses, HSF1 and NRF2, Promote P62/SQSTM1 And KSHV Lytic Antigen Expression in TB-or BZ-Treated PEL Cells p62/SQSTM1 is a common transcription target of HSF1 and NRF2, activated during the main mammalian cellular responses to stress (the heat shock and anti-oxidant responses, respectively) [9] . In order to investigate the role HSF1 and NRF2 in p62/SQSTM1 up-regulation and the activation of KSHV lytic antigen expression, we pharmacologically inhibited these transcription factors. In a dose response assay, we found that the HSF1 inhibitor KRIBB11 (I-HSF1) used at 5 µM was able to reduce HSF1 activity, as revealed by the decreased expression of its target heat shock protein (HSP) 70 ( Figure 6A ), and reduced p62/SQSTM1 and K-bZIP expression in TB-or BZ-treated PEL cell lines ( Figure 6B) . Furthermore, the inhibition of NRF2 by brusatol (I-NRF2) at concentrations able to reduce NRF2 expression (5 nM) ( Figure 6C ), decreased p62/SQSTM1 and K-bZIP expression ( Figure 6D ), suggesting that both HSF1 and NRF2 transcription factors played a role in the KSHV lytic antigen expression induced by TB or BZ in PEL cells. Given that pharmacological inhibitors could have off-target effects, to better elucidate the role of these transcription factors in KSHV lytic antigen expression and p62/SQSTM1 up-regulation, we performed HSF1 or NRF2 silencing by using specific siRNA. As shown in Figure 7A ,B, HSF1 and NRF2 knocking-down reduced both p62/SQSTM1 and K-bZIP expression in TB-and BZ-treated cells. The results confirmed the reduction of the percentage of K-bZIP-positive cells in NRF2 and HSF1 silenced cells undergoing TB or BZ treatment ( Figure 7C ). Considered together, these results indicate that the main mediators of cellular responses to stress, HSF1 and NRF2, and their target p62/SQSTM1, played a role in the induction of KSHV lytic antigen expression induced by TB or BZ in PEL cells. Notably, p62/SQSTM1 siRNA reduced NRF2 expression ( Figure 7D ), in agreement with previous studies indicating that a positive feedback loop between the two molecules may occur [28] [29] [30] . β-Actin was used as a loading control. Densitometric analysis was performed using Image J software and the ratio of HSP70 or NRF2 versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of three independent experiments. (B) and (D): K-bZIP lytic antigen and p62/SQSTM1 expression in TB-or BZ-treated PEL cells in the presence or absence of HSF1 (5 µM) or NRF2 (5 nM) inhibitors (I-HSF1 and I-NRF2) was analyzed by western blotting after 24 h of treatment. Densitometric analysis was performed using Image J software and the ratio of K-bZIP or p62/SQSTM1 versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of three independent experiments. p* < 0.05 (TB/I-HSF1 or I-NRF2 vs TB), p** < 0.05 (BZ/I-HSF1 or I-NRF2 vs BZ). Densitometric analysis was performed using Image J software and the ratio of NRF2 versus β-Actin was calculated. Histograms represent the mean ± standard deviation (SD) of three independent experiments. p** < 0.05 (siRNA SQSTM1 vs siRNA SC, TB-treated), and p*** < 0.05 (siRNA SQSTM1 vs siRNA SC, BZ-treated).
HSF1 and
3.6. The Inhibition of HSF1, NRF2 and p62/SQSTM1 (siRNA) Further Increases ROS and Cytotoxicity Induced by TB or BZ in PEL Cells
Since HSF1, NRF2 and p62/SQSTM1 proteins may be activated in the course of oxidative stress, we evaluated the level of intracellular ROS in PEL cells treated with TB or BZ in the presence or absence of HSF1 or NRF2 inhibitors KRIBB11 (I-HSF1) and brusatol (I-NRF2) respectively. SQSTM1 (siRNA) was also evaluated. As shown in Figure 8A , HSF1 and NRF2 inhibitors led to a further increase of ROS level in comparison with TB or BZ single treatments, and similarly, SQSTM1 RNA knocking-down also exerted this effect ( Figure 8B ), likely due to the positive feedback loop between p62 and NRF2 [28, 29] . These results suggest that HSF1, NRF2 and p62/SQSTM1 are required to maintain the ROS increase at a moderate level, allowing KSHV lytic cycle activation in TB-or BZ-treated PEL cells. Indeed, when ROS level further increased by the combination of TB or BZ with SQSTM1 silencing, HSF1 or NRF2 inhibition, the cytotoxicity increased ( Figure 8C ,D) and likely rendered the cellular environment unsuitable for viral replication. This hypothesis was confirmed by the findings that NAC supplementation rescued the ability of TB to activate KSHV p64 lytic antigen expression ( Figure 8E ) and to induce viral release ( Figure 8F ) in the presence of HSF1 inhibitor. Conversely, the addition of H 2 O 2 to TB reduced KSHV late lytic expression ( Figure 8G ), further highlighting that the ROS level is critical for virus replication. 
Discussion
The results obtained in this study indicate that cytotoxic drugs which increase ROS levels, such as TB and BZ, activate the KSHV lytic cycle, while those that decrease ROS levels, such as MET and Q, although cytotoxic for PEL cells, fail to do so. Therefore, the induction of viral reactivation from latency appears to correlate with the increase or decrease of intracellular ROS, whose role was highlighted by the use of NAC that prevented viral lytic antigen expression in TB-or BZ-treated PEL cells. Previous studies have attempted to investigate which molecular mechanisms could be responsible for lytic cycle activation by some cytotoxic treatments. It has been reported, for example, that the induction of apoptosis is neither necessary nor sufficient to induce gammaherpesvirus replication [25, 31, 32] . Additionally, autophagy activation, while promoting the replication of gammaherpesviruses such as KSHV and EBV, is not sufficient per se to trigger the replicative process [21, 27] . Indeed, as we have previously demonstrated, quercetin (Q) and metformin (MET) are able to activate autophagy in PEL cells [4, 5] , similar to BZ or TB treatments [2, 25] .
The role of oxidative stress in activating KSHV has been shown by our laboratory and that of others [6, 33] . Besides confirming the importance of ROS in reactivating KSHV from latency, this study also suggests that, in order to allow KSHV to reactivate from latency in PEL cells, ROS increases must be kept to moderate levels by HSF1 and NRF2 transcription factors and p62/SQSTM1 [9] . Their pharmacologic or genetic inhibition indeed further increased ROS in comparison to TB or BZ single treatments, likely rendering the cellular environment unsuitable for viral replication. Indeed, the targeting of HSF1 and NRF2, as well as p62/SQSTM1 silencing, enhanced the cytotoxic effect of TB or BZ treatments in PEL cells.
It is possible that different levels of ROS determine whether KSHV remains latent or switches to a lytic cycle or no longer replicates. In particular, when the ROS level is low, KSHV continues to remain in a latent state; conversely, when the ROS level slightly increases, the virus may sense the cellular stress and starts replicating before cells will possibly end up dying. Accordingly, a mild ROS increase has been shown to induce a low DNA damage that may lead to the activation of the growth arrest function of wild type p53, through the transcription of p21. Interestingly, the p53-p21 axis has been reported to be essential for KSHV replication [3, 8] . However, when the level of ROS is too high, the activation of the pro-apoptotic function p53 may occur [34] and cell death may be induced [35] .
Regarding BZ, it has been previously reported that it induces an ROS increase in lymphoma cells [36] and induces Endoplasmic Reticulum (ER) stress [37] . We have previously shown that BZ also induced ER stress in PEL cells and that through this effect it activated the autophagic process [2, 25] . As stated above, ROS plays a role in activating KSHV replication during several treatments [6, 33] . Interestingly, the inhibition of NRF2, the main mediator of the antioxidant response, may reactivate KSHV from latency [13] . However, based on the results obtained in this study, we observed that, in order to activate KSHV replication, the increase of ROS must be kept at a moderate level by HSF1, NRF2 and p62/SQSTM1 (Figure 9 ). It is a clever strategy for viruses to initiate a lytic replication in cells undergoing mild stress that could possibly increase and lead to a condition in which both cellular and virus survival is no longer guaranteed. The latter event occurs when the level of ROS is too high or, conversely, too low. Indeed, in comparison to normal cells, cancer cells are usually dependent on a higher level of ROS that promotes cell survival by maintaining activated oncogenic pathways, such as PI3K and NF-κB [38] . Accordingly, we have observed MET or Q treatments that reduced ROS and the activation of oncogenic pathways induced PEL cell death [4, 5, 39] .
In conclusion, this study suggests that targeting ROS or the pathways that regulate the ROS level, such as NRF2, HSF1 or p62/SQSTM1, could be a promising strategy to increase PEL cell death and concomitantly restrain viral replication induced by cytotoxic drugs such as TB or BZ. 
